Aramco’s Prosperity7 Ventures Invests $14 Million in Cispoly
Cispoly was founded in 2020 by Liu Pei and is focused on the early diagnosis of gynecological tumors.
Prosperity7 Ventures, Saudi Aramco Ventures' $1 billion VC fund, has invested $14 million in a Series B round of Shenzhen Cispoly Bio-Tec, a Beijing-headquartered women's health company.[1] Existing shareholder Sunland Fund also participated in the funding round.
Cispoly was founded in 2020 by Liu Pei and works on the early diagnosis of gynecological tumors. It is also involved in the development of products for endometrial cancer screening. China's National Medical Products Administration approved Ciscer, Cispoly's main product for real-time cervical cancer screening, in March.
Future products include Cisova, which aids in early detection of ovarian cancer, which is almost ready for commercial testing. Anothe product, Cisendo, is an endometrial cancer screening solution that is now undergoing clinical trials. Cispoly plans to use the Series B financing to speed up product registration, facilitate global expansion, and research and development.
Cispoly has agreements with medical institutes and aims to grow across Southeast Asia and Europe.
Prosperity7 Ventures, which officially launched in February 2022 but began operations in 2021, has previously invested in Chinese health-tech startups. [2] In 2021, it co-led healthtech Fourier Intelligence in its Series C and D rounds. Fourier Intelligence produces exoskeleton robotics devices for rehabilitation activity. [3]
Femtech, a nascent technology-enabled industry that focuses on women's health, is on the rise in the region. Femtech includes companies working in reproductive health and contraception, pregnancy and nursing, pelvic and uterine healthcare, women's wellness, menstrual and sexual health, menopause care and mental health. Femtech companies typically utilize apps and telehealth resources, deeptech, and devices like wearables, sensors and remote patient monitoring.